2 citations
,
March 2014 in “Turkderm” Mesotherapy and platelet-rich plasma treatments may help with hair loss, but their safety and effectiveness are still uncertain.
June 2025 in “Experimental and Сlinical Urology” This research found that the new combination drug Predstanormix Duo, with dutasteride and tamsulosin, is bioequivalent to established treatments for benign prostatic hyperplasia, showing similar pharmacokinetics and safety, potentially improving treatment availability and adherence in high-risk patients.
January 2020 in “International Journal of Research in Pharmacy and Chemistry” This study developed a validated HPLC method for accurately estimating dutasteride and its related compounds in capsules, suitable for routine and stability sample analysis.
June 2025 in “Journal of Drug Delivery Science and Technology” A dissolving microneedle patch with dutasteride offers effective, long-lasting hair loss treatment with fewer side effects.
January 2017 in “Rasayan journal of Chemistry” This paper describes a new scalable synthesis method for Dutasteride, highlighting its potential for large-scale commercial production.
4 citations
,
May 2019 in “Asian Journal of Pharmaceutical Sciences” This study found that a dutasteride tablet formulation using cyclodextrin complex, solubilizing polymer, and surfactant achieved similar bioavailability in beagle dogs to that of a commercial capsule.
October 2023 in “Open Repository of the University of Porto (University of Porto)” 16 citations
,
June 2015 in “Drug Design Development and Therapy” This study found that a gelatin microparticle-containing self-microemulsifying formulation combined with Soluplus improved the oral absorption of dutasteride.
August 2023 in “MPPKI (Media Publikasi Promosi Kesehatan Indonesia) : The Indonesia journal of health promotion” In this study, researchers used a UV-Vis Spectrophotometer to qualitatively and quantitatively analyze Dutasteride residues in human plasma, achieving a total recovery rate of 64.992%, and determined that the BTB reagent effectively selected compounds not analyzed in their research.
June 2024 in “International Journal of Pharmaceutical Quality Assurance” This study established a new reverse-phase high-performance liquid chromatography method to accurately and precisely quantify silodosin and dutasteride in mixtures, meeting International Council of Harmonization validation criteria for stability, sensitivity, and recovery.
September 2013 in “Metal Powder Report” This study found that dihydrotestosterone induces hair loss in male C57BL/6 mice, and this effect can be partially reversed by the androgen receptor antagonist bicalutamide.
October 2020 in “Open Repository of the University of Porto (University of Porto)” May 2023 in “Journal of Pharmaceutical Innovation”
December 2024 in “International Journal of Drug Delivery Technology” This study reports that a novel Nano-Structured Lipid Carrier system for delivering dutasteride may enhance its anticancer effects while reducing systemic side effects in clinical settings.
January 2024 in “International Journal of Biological and Environmental Investigations” This study developed and validated a reliable RP-HPLC method for accurately quantifying dutasteride in pharmaceutical formulations and bulk pharmaceuticals using a Shiseido C18 analytical column, demonstrating precision, accuracy, and sensitivity across a concentration range of 10 to 22 ppm.
September 2015 in “한국임상약학회지” In this study, both the topical minoxidil 7%/dutasteride 0.5 mg and topical minoxidil 7%/finasteride 1 mg treatments for androgenetic alopecia showed high effectiveness, but the dutasteride combination was associated with greater efficacy and more adverse effects.
April 2022 in “Reactions Weekly” February 2006 in “Inpharma Weekly”
March 2026 in “Pharmaceutics” This review discusses therapeutic deep eutectic solvents as promising "green" solutions for enhancing drug solubility and delivery through the skin, reporting no new clinical results and highlighting future research directions.
12 citations
,
February 2003 in “European Urology Supplements” Dutasteride reduces DHT more effectively than finasteride.
June 2008 in “Drugs & therapy perspectives” Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.
408 citations
,
May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.
September 2023 in “Forum Dermatologicum” Dutasteride injections can help treat hair loss in men and women.
33 citations
,
December 2005 in “British Journal of Clinical Pharmacology” This study found that the Transdermal Delivery System efficiently delivers testosterone systemically and showed bioequivalent hormone concentrations to a known topical gel in healthy males.
8 citations
,
January 2021 in “Pharmaceutics” This study found that using nanoporous silica entrapped lipid-drug complexes enhanced the solubility and bioavailability of dutasteride in beagle dogs.
26 citations
,
September 2018 in “Neurobiology of Disease” This study found that both finasteride and dutasteride significantly reduced L-DOPA-induced dyskinesia in a rat model of Parkinson's disease, with dutasteride showing greater effectiveness at lower doses.
October 2025 in “Open Repository of the University of Porto (University of Porto)” Dutasteride is more effective than finasteride for hair growth, and sublingual apomorphine quickly improves Parkinson's symptoms.
October 2006 in “Urology” The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
October 2025 in “Transplantation” This study developed dutasteride-loaded microneedle systems using a specific polymer to enhance transdermal delivery, demonstrating efficient drug release and increased accumulation in hair follicles, thus supporting their potential for treating androgenic alopecia.
November 2024 in “Nanomaterials” This study formulated and characterized a dutasteride-loaded nanocrystalline suspension for long-acting parenteral delivery, finding that it provided sustained drug release in rats with a significant reduction in local inflammation over 28 days following intramuscular injection.